Skip to main content
SpringerLink
Log in

Overview of the Pharmacokinetics of Isosorbide-5-Mononitrate

  • Conference paper
Mononitrate II

Part of the book series: International Boehringer Mannheim Symposia ((BOEHRINGER))

  • 40 Accesses

Abstract

One of the problems of prophylactic antianginal therapy with organic nitrates is without doubt their high first pass effect after oral administration. First observation of a complete inactivation of several organic nitrates when infused into the portal vein of anaesthesized rats prompted Needleman et al. [22] to claim even a total ineffectivness of nitrates when given orally for therapy. Although today we know with certainty from quite a number of experimental and clinical studies that this extreme postulate does not apply (for details see Abshagen [3]), the bioavailability of widely used nitrates such as trinitroglycerin or isosorbide dinitrate (ISDN) is rather poor and unsatisfactory [4, 23, 24, 31].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Abshagen U, Spörl-Radun S (1981 a) First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man. Eur J Clin Pharmacol 19: 423–429

    Article  PubMed  CAS  Google Scholar 

  2. Abshagen U, Betzien G, Endele R, Kaufmann B (1981 b) Pharmacokinetics of intravenous and oral isosorbide-5-mononitrate. Eur J Clin Pharmacol 20: 269–275

    Article  PubMed  CAS  Google Scholar 

  3. Abshagen U (1985) Organic Nitrates. In: Abshagen U (ed) Clinical pharmacology of antianginal drugs. Springer, Berlin Heidelberg New York, pp 287–364 (Handbook of experimental pharmacology, vol 76)

    Chapter  Google Scholar 

  4. Abshagen U, Betzien G, Endele R, Kaufmann B, Neugebauer G (1985) Pharmacokinetics and metabolism of isosorbide dinitrate after intravenous and oral administration. Eur J Clin Pharmacol 27: 637–644

    Article  PubMed  CAS  Google Scholar 

  5. Akpan W, Endele R, Neugebauer G, Steudel H (1985) Pharmacokinetics ofIS-5-MN after oral and intravenous administration in patients with hepatic failure. In: Cohn IN, Rittinghausen R (eds) Mononitrates. International Boehringer Mannheim symposia, Montreux, 1984. Springer, Berlin Heidelberg New York Tokyo, pp 53–66

    Google Scholar 

  6. Boedigheimer K, Nowak FG, Delius W (1981) Vergleichende invasive Untersuchung liber die Wirkung von Isosorbid-5-Mononitrat und IsOsorbiddinitrat bei chronischer Herzinsuffizienz. Med Welt 32, 14a: 543–547

    Google Scholar 

  7. Bogaert MG, Rosseel MT (1972) Vascular effects of the dinitrate and mononitrate esters of isosorbide, isomaunide and isoidide. Naunyn Schmiedeberg’s Arch Pharmacol 275: 339–342

    Article  CAS  Google Scholar 

  8. Bogaert MG, Rosseel MT (1980) Plasma levels ofisosorbide dinitrate and the isosorbide mononitrates after increasing doses of a retard preparation of isosorbide dinitrate. Nouv Presse Med 9: 2423–2427

    Google Scholar 

  9. Bogaert MG, Rosseel MT, Boelaert J, Daneels R (1981) Fate of isosorbide dinitrate and mononitrates in patients with renal failure. Eur J Clin Pharmacol 21: 73–76

    Article  PubMed  CAS  Google Scholar 

  10. Bogaert MG and Rosseel MT (1983) Fate of orally given isosorbide dinitrate in man: factors of variability. Z Kardiol 72: 11–13

    PubMed  Google Scholar 

  11. Bruyneel K, Rosseel MT, Bogaert MG (1982) Plasma concentrations of isosorbide dinitrate and mononitrates after acute and chronic oral administration of isosorbide dinitrate in man. Arzneim Forsch 32: 769–772

    CAS  Google Scholar 

  12. Chasseaud LF, Taylor T (1980) Plasma concentrations and comparative biovailability of isosorbide dinitrate after sublingual, oral or cutaneous doses to human subjects. In: Rudolph W, Schrey A (eds) Nitrate II. Urban and Schwarzenberg, Munich, p 22

    Google Scholar 

  13. Down WH, Chasseaud LF, Grundy RK (1974) Biotransformation of isosorbide dinitrate in humans. J Pharm Sci 63: 1147–1149

    Article  PubMed  CAS  Google Scholar 

  14. Evers J, Krakampo B, Klimkait W, Dickmans HAS, Maddock J, Luckow V, Cawello V, Weill M (1986) Pharmacokinetics of isosorbide-5-nitrate in renal failure. Eur J Clin Pharmacol 30: 349–350

    Article  PubMed  CAS  Google Scholar 

  15. Fung HL, McNiff EF, Ruggirello D, Darke A, Thadani U, Parker JO (1981) Kinetics of isosorbide dinitrate and relationships to pharmacological effects. Br J Clin Pharm 11: 579–590

    CAS  Google Scholar 

  16. Jones JP (1986) Dose response of IS-5-MN in the control of stable angina. This volume

    Google Scholar 

  17. Kösters W, Klotschkoff P, Abshagen U (1981) Pharmakokinetik von Isosorbid-5-Mononitrat bei Patienten mit fortgeschrittener Niereninsuffizienz. Med Welt 32: 521–523

    PubMed  Google Scholar 

  18. Major RM, Taylor T, Chasseaud LF, Darragh A, Lambe RF (1984) Isosorbide 5-mononitrate kinetics. Clin Pharmacol Ther 35: 653–659

    Article  PubMed  CAS  Google Scholar 

  19. Mannebach H, Ohlmeier H, vMollendorff E, Gleichmann U, Abshagen U (1981) Steady state kinetik von Isosorbid-5-Mononitrat bei Patienten mit koronarer Herzkrankheit. Med Welt 32/14a: 517–520

    PubMed  CAS  Google Scholar 

  20. Michel D (1976) Der Einfluß von Metaboliten des lsosorbiddinitrats auf das Belastungs-EKG bei Koronarinsuffizienz. HerzlKreisl 8: 444–447

    Google Scholar 

  21. Morrison RA, Wiegand UW, Jähnchen E, Höhmann D, Kapser W, Meinertz T, Fung HL (1983) Hepatic extraction of isosorbide dinitrate in cardiac patients. Clin Pharmacol Ther 34: 724–731

    Article  PubMed  CAS  Google Scholar 

  22. Needleman P, Lang S, Johnson EM jr (1972) Organic Nitrates: Relationship between biotransformation and rational angina pectoris therapy. J Pharmacol Exp Ther 181: 489–497

    PubMed  CAS  Google Scholar 

  23. Platzer R, Reutemann G, Galeazzi RL (1982) Pharmacokinetics of intravenous isosorbide dinitrate. J Pharmacokinet Biopharm 10: 575–585

    Article  PubMed  CAS  Google Scholar 

  24. Porchet H, Bircher J (1982) Noninvasive assessment of portalsystemic shunting: Evaluation of a method to investigate systemic availability of oral glyceryl trinitrate by digital plethysmography. Gastroenterology 82: 629–637

    PubMed  CAS  Google Scholar 

  25. Raue F, Ritz E, Akpan W, Endele R and Neugebauer G (1985) Kinetics of IS-5-MN and its glucuronide in patients with renal failure. In: Cohn IN, Rittinghausen R (eds) Mononitrates. International Boehringer Mannheim symposia. Springer, Berlin Heidelberg New York Tokyo, pp78–85

    Google Scholar 

  26. Reifart N, Bussmann WD, Schirmer M, Kaltenbach M (1981) Hämodynamische Wirksamkeit, Wirkdauer und Pharmakokinetik von 80 mg Isosorbid-5-Mononitrat bei frischem Herzinfarkt. Med Welt 32: 540–542

    PubMed  CAS  Google Scholar 

  27. Spörl-Radun S, Betzien G, Kaufmann B, Liede V, Abshagen U (1980) Effects and pharmacokinetics of isosorbide dinitrate in normal man. Eur J Clin Pharmacol 18: 237–244

    Article  PubMed  Google Scholar 

  28. Stauch M, Grewe N, Nissen H (1975) Die Wirkung von 2- und 5-Isosorbidmononitrat auf das Belastungs-EKG von Patienten mit Koronarinsuffizienz. Verh Dtsch Ges Kreislaufforsch 41: 182–184

    PubMed  CAS  Google Scholar 

  29. Taylor T, O’Kelly DA, Major RM, Darragh A, Chasseaud LF (1978) Plasma concentrations of isosorbide dinitrate after administration of increasing doses of a sustained-release formulation to human subjects. Arzn Forsch/Drug Res 28: 1426–1428

    CAS  Google Scholar 

  30. Taylor T, Chasseaud LF, Major R, Doyle E (1981) Isosorbide-5-Mononitrate pharmacokinetics in humans. Biopharm Drug Dispos 2: 255–263

    Article  PubMed  CAS  Google Scholar 

  31. Taylor T, Chasseaud LF, Doyle E, Bonn R, Darragh A, Lambe RF (1982) Isosorbid dinitrate pharmacokinetics. Arzneim-Forsch/Drug Res 32: 1329–1333

    CAS  Google Scholar 

  32. Ulbrich T, Jansen W, Osterspey A, Gabrielsen F, Tauchert M (1984) Zur Frage der optimalen Dosierung von Mononitraten. In: Verh Dtsch Ges für Innere Medizin, 90. Kongress. Bergmann, Munich, pp 1380–1384

    Google Scholar 

  33. Wendt RL (1972) Systemic and coronary vascular effects of the 2- and the 5-mononitrate esters of isosorbide. J Pharmacol Exp Ther 180: 732–742

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. U. Abshagen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. British Heart Foundation, 102 Gloucester Place, London, W1H 4DH, UK

    D. G. Julian Prof. M.D. (Medical Director) (Medical Director)

  2. Clinical Research Boehringer Mannheim GmbH, Sandhofer Straße 116, 6800, Mannheim 31, Federal Republic of Germany

    R. Rittinghausen M.D. (Director) (Director)

  3. Cardiovascular Clinical Research Boehringer Mannheim GmbH, Sandhofer Straße 116, 6800, Mannheim 31, Federal Republic of Germany

    H. J. Überbacher M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Abshagen, U. (1987). Overview of the Pharmacokinetics of Isosorbide-5-Mononitrate. In: Julian, D.G., Rittinghausen, R., Überbacher, H.J. (eds) Mononitrate II. International Boehringer Mannheim Symposia. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72689-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-72689-7_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-17832-3

  • Online ISBN: 978-3-642-72689-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation